Sakar Healthcare posts strong Q2 growth and sets multiyear oncology targets

Management guided margin improvementOrder pipeline disclosedMulti-year targets disclosedInvestor Communications View source PDF Explain this filing

SAKAR · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.0%Reaction day

₹931.10

prior close

₹950.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.3%+0.7% vs market

Pharmaceuticals peers, median of 170sector+0.1%+0.8% vs sector

On the reaction day the stock moved 0.7 pts more than Nifty Microcap 250 and 0.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.1

10m

-0.1

15m

-0.3

30m

+0.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.0+0.3+0.7+0.1+0.8

Next day

+5.1+2.4+2.7+1.1+4.0

+8.9+3.6+5.3+2.0+7.0

+4.7pendingpending+1.8+2.9

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 170Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Q2 FY27 revenue rose 52% year on year to INR 87.42 crore, while EBITDA rose 114% and margin improved to 28% from 20%. Profit after tax rose 149% to INR 11.31 crore. Management reported 69 oncology contracts and 45 more opportunities. It expects oncology to exceed 60% of revenue in two to three years, with EBITDA reaching 34% to 35% after further API integration.

Likely market impact

Strong growth and margin gains support sentiment, but future targets depend on converting approvals into sales and completing API integration.